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A pilot study of concurrent whole-brain radiotherapy
and chemotherapy combined with cisplatin, vindesine
and mitomycin in non-small-cell lung cancer with brain
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Summary We have evaluated the feasibility, toxicity, and tumour response of concurrent whole-brain radiotherapy (WBRT) and chemo-
therapy with cisplatin, vindesine and mitomycin in the treatment of 33 patients with brain metastasis from non-small-cell lung cancer (NSCLC).
The imaging response demonstrated that 25 patients (75.8%) responded to brain lesions, including five complete responders, and the
response rate to primary lesion was 18%. The treatment improved at least one grade of performance status in 30% and of neurological
functions in 55% of the patients. The major toxicity was leucopenia (2 grade 3, 84.4%). Median survival was 9.7 months and the 1-year
survival rate was 40%. Concurrent WBRT and chemotherapy can be safely administered to patients with brain metastasis from NSCLC, with
a remarkable response rate, improvement of neurological functions and encouraging survival duration.
Keywords: whole-brain radiotherapy (WBRT); concurrent whole-brain radiotherapy and chemotherapy; cisplatin; vindesine; mitomycin;
non-small-cell lung cancer
Resection of single-brain metastasis and post-operative whole-
brain radiotherapy (WBRT) can improve survival compared with
treatment using WBRT alone (Horton, 1971). For this reason,
surgical resection has become part ofthe standard management of
appropriately selected patients with inactive extracranial disease
(Kornblith et al, 1985; Patchell et al, 1990; Vecht et al, 1993).
In most instances, brain metastases are multiple and occur in
the presence of metastasis to other organs (Sundaresan et al,
1993). WBRT rather than surgery has been used as the primary
treatment modality in the management of brain metastasis. More
than 75% of patients benefit symptomatically from WRBT for
a short time, and median survival varies from 15 to 18 weeks
(Lee et al, 1989).
As most patients have disseminated disease, more attention
should be paid to the use ofsystemic chemotherapy in brain metas-
tases, which could offer control of cranial as well as extracranial
disease. Chemotherapy for brain metastases has been considered
ineffective because thedrugs do not penetrate the intact blood-brain
barrier (BBB). However, some reports have demonstrated a break-
down ofthe BBB in metastatic brain tumours, which diminishes the
restrictions in the transport of drugs normally exerted (Workman,
1986; Greig, 1989). Several studies have reported a higher concen-
tration of drugs in brain tumours than in the brain or an increased
tumour-plasma ratio (Stewart et al, 1979, 1983, 1984).
The mitomycin, vindesine and cisplatin (MVP) regimen has
demonstrated neurological improvement and good response in
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patients with brain metastasis from NSCLC in Japan (Kasamatsu
et al, 1990; Yamamoto and Furuse et al, 1995).
The combination of chemotherapy and radiotherapy could
increase cytotoxicity by interfering with cells' ability to repair
injury caused by the other treatment. In this manner, combined
treatments could result in additive or supra-additive cytotoxic
effects. Also, there are laboratory data to suggest that cisplatin
increases radiation sensitivity (Kornblith et al, 1985).
The objective ofthis study is to evaluate the technical feasibility,
toxicity and tumourresponse ofconcurrent WBRT and MVP in the
treatment ofpatients with brain metastasis from NSCLC.
PATIENTS AND METHODS
Eligibility
Patients had to fulfil all the following criteria to be entered in the
study: a histologically or cytologically proven diagnosis of
NSCLC; stage IV with brain metastasis; an Eastern Cooperative
Oncology Group (ECOG) performance status (PS) of < 3; age less
than 75 years; no massive pleural effusion; no severe pain due to
bone metastasis; adequate haematological [Hb > 9.5 g dl-', white
blood cell count . 4000 gl-', platelet (PLT) count 2 100 000 g 1-'],
hepatic (serum bilirubin < 2.0 mg dl'; ALT, AST and alkaline
phosphatase < double upper limit of normal) and renal (serum
creatinine < 1.1 mg dl-') functions; no active concomitant malig-
nancies; no previous treatment of primary or brain lesion; and no
consciousness disturbance or systemic convulsion. Informed
consent was obtained from all patients.
Treatment
Chemotherapy consisted of vindesine (3 mg m-2 on days 1, 8, 29
and 39), cisplatin (100 mg m-2 on days 1 and 29) and mitomycin
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Table 1 Neurological function classification
1. Able to work or to perform normal activities: neurological finding minor or
absent
2. Able to carry out normal activities with minimal difficulties. Neurological
impairment does not require nursing care or hospitalization
3. Seriously limited in performing normal activities. Requiring nursing care or
hospitalization. Patients confined to bed or wheelchair or have significant
intellectual impairment
4. Unable to perform even minimal normal activities. Requiring
hospitalization and constant nursing care and feeding. Patients unable to
communicate or in coma
weeks. If neurological symptoms occurred after WBRT, brain CT
was again performed. The responses of brain metastastic lesion
and primary tumours were evaluated according to the World
Health Organization (WHO) criteria (1979).
The duration of response was measured from the first day of
treatment with concurrent WBRT and chemotherapy. Brain failure
was defined as recurrence of tumour-anywhere in the brain. The
survival was calculated on the basis of the period from the start of
the treatment to death or the last follow-up.
Criteria are from Borgelt et al (1980). Toxicity
Table 2 Survival of all patients (n = 33)
Estimated median 95% Confidence P-value
Variable survival (days) interval (days) (log-rank test)
Median age 62 years (range 39-73)
<65 years (20)a 311 132-449 0.7131
>65 years (13) 290 133-409
Sex
Male (16) 187 104-366 0.0689
Female (17) 409 191-117
PS
0-1(1+13) 311 191-117 0.8352
2-3(11+8) 210 117-449
Histology
Adenocarcinoma
large cell (26+4) 299 144-449 0.3588
Squamous cell (4) 284 72-404
Brain symptoms
Yes (23) 311 133-449 0.7321
No (10) 234 191-455
Brain lesion
Single (19) 366 291-492 0.0288
Multiple (14) 163 85-378
Other metastatic lesion
Yes (23) 210 132-404 0.0795
No(10) 378 290-660
FN
0-1 (17) 299 210-409 0.8024
2-4 (16) 164 117-449
aNumbers in parentheses are numbers of patients.
(8 mg m-2 on days 1 and 29). The doses were modified on the basis
of blood counts and renal functions on the day of therapy (Furuse
et al, 1995).
On day 2 of chemotherapy, WBRT was administered using a
linear accelerator for 5 weeks at a dose of 2 Gy given 20 times.
The dose was given in five fractions per week.
Response
Treatment response was evaluated through periodic reassessment of
PS and neurological function (FN) as described by Borgelt (1980)
and the Radiation Therapy Oncology Group (Table 1). Patients
were evaluated before treatment-weekly for the first 4 weeks,
monthly for 2 or more months and every 3 months thereafter.
Response to brain lesions was evaluated by contrast-enhanced
brain computerized tomography (CT) before treatment and 8
weeks after treatment. If the findings showed partial or complete
response after WBRT, these responses were reconfirmed after 4
Patients were evaluated every week during WBRT and chemo-
therapy. Toxicity was rated according to WHO criteria (1979).
Statistical methods
Survival was calculated on the basis ofthe period from the start of
treatment to death or the last follow-up. The survival curve was
calculated by the method of Kaplan and Meier.
Available treatment variables, which in some other series
proved to have influence on the treatment ofNSCLC, were inves-
tigated for any possible relationship to the probability of survival
as a result of the treatment of NSCLC, first in univariate analysis
and subsequently by application of a multiple regression model.
The univariate was based on 2 x 2 tables, and differences were
tested by use of the chi-square test. A P-value of 0.05 was
regarded as significant.
Differences in survival duration were compared using a two-
sided log-rank test (Mantel, 1966). To adjust for any confounding
variables and to assess the relative importance of different prog-
nostic variables for survival, Cox's proportional hazards model
(1972) was used.
RESULTS
Distribution of prognostic factors
From April 1991 to August 1994, 33 patients were entered into
this study. The distribution of the patients' prognostic factors is
given in Table 2. The estimated median survival of all patients
from the start of treatment to death or the last follow-up was 229
days, with 30% being alive I year after treatment (Figure 1). The
effects of a number ofpotential prognostic factors on survival was
examined initially using univariate analysis (Table 1). Patients
with a single metastatic lesion survived longer than those with
multiple lesions (P = 0.0288). Other prognostic factors had no
significant effect on survival.
Stepwise multiple regression analysis was carried out to deter-
mine the prognostic factors, except for histology, significantly
influencing survival. The only statistically significant prognostic
factor found to be associated with survival was the number of
brain metastatic lesions (P = 0.0339).
Toxicity
In total, 63 courses of MVP were given. Twenty-six patients
received two courses, three patients three courses and five only one
course. The toxicities observed during the entire treatment of 33
patients are listed in Table 3. The main toxicity was myelosuppres-
sion, in particular leucopenia. Of the 33 patients, 28 (84.8%)
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Figure 1 Changes of scores in PS and FN after WBRT and MVP
Table 3 Toxicity in 33 patients
Toxicity WHO No. of toxicities
2 grade 3(%)
1 2 3 4
Leucopenia 0 5 19 9 84.8
Thrombocytopenia 5 7 5 3 24.2
Anaemia 5 13 7 1 3.0
Nausea/vomiting 11 16 1 0 0
Neutropenic fever 0 2 0 0 0
Infection 4 3 0 0 0
Elevation of serum creatinine 8 2 2 0 6.0
Elevation of transaminases 2 0 0 0 0
Elevation of alkaline phosphatase 2 0 0 0 0
Table 4 Response to treatment
No. of Response(%) Total
patients response rate(%)
CR PR NC PD NE
Brain metastases
Overall 33 5(15) 20(61) 7 0 1 75.8a
Solitary lesion 19 4 (21) 10 (53) 5 0 0 73.7
Multiple lesions 14 1 ( 4) 10 (42) 2 0 1 45.8
Primary tumour 33 0 6 (18) 22 0 5 18.2
a95% Confidence interval 57.74-88.90%. CR, Complete response; PR, partial response; NC, no change; PD, progressive disease; NE, not eligible. Numbers in
parentheses are percentages.
Response
experienced grade 3 or 4 leucopenia. Grade 3 or 4 thrombocy-
topenia was observed in eight patients (24.2%). Grade 3 anaemia
was observed in one patient (3%). Thirty-three per cent of the
patients experienced grade 1 nausea and vomiting, 48% grade 2 and
3% grade 3. We did not experience treatment-related death or toxi-
city of the central nervous system as a result ofWBRT and MVP.
The total response rate for brain lesions in these 33 patients was
75.8% as shown in Table 4 (five complete responses (CR) and 20
partial responses (PR), 95% confidence interval 57.74-88.90%).
One patient was not assessable. Ofthe 25 patients who had a CR or
PR after WBRT and MVP, five patients had local brain recurrence
with neurological symptoms at 129, 226, 321, 576 and 877 days
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cancer (Boogerd et al, 1992) describe response rates in the brain
similar to those in other organ sites. Kasamatsu et al (1990) in
Japan reported on a study in which five patients with NSCLC and
brain metastases were treated with a mitomycin, vindesine and
cisplatin regimen. Of the five patients, three had a PR for brain
lesion and five showed neurological improvement. Their survival
time ranged from 6 to 8 months. Also, Yamamoto et al (1993)
reported that 22 NSCLC patients associated with brain metastasis
were treated with chemotherapy regimens including cisplatin, with
three patients having a CR and two a PR for brain lesions.
In patients with malignant gliomas, adjuvant chemotherapy in
addition to WBRT increased the number of long-term survivors
200 400 600 800 1000 (Walker et al, 1978). Hidalgo et al (1987) reported, in his series,
Days that five patients with NSCLC and brain metastases were treated
Overall survival of 33 eligible patients treated with WBRT and MVP with weekly cisplatin (40-60 mg m-2) during WBRT (50 Gy over
5 weeks). Three patients had a CR and two a PR to the treatment,
and four were alive more than 6 months later. Also, Lange et al
(1987) reported that 27 patients with NSCLC and brain metastases
e treatment. The median duration of response for brain were treated with ifsofamide (daily for 5 days at 2 g m-2) and
was 223 days (range 43-892 days). In 33 primary lung BCNU (at 30 mg m-2 on days 1,3 and 5) and radiotherapy was
six (18%) had a PR after WBRT and MVP. given simultaneously. Of the 27, seven patients had a CR and 12 a
PR. The mean time of survival was 9.5 months for patients with
NSCLC. In an uncontrolled study ofpatients with brain metastases
from solid tumours, concurrent radiotherapy and chemotherapy
tion of performance status and neurological function appeared to increase the median survival, although no information
ing to response is shown in Figure 1. Among the 33 was provided regarding the extent of extracranial metastatic
s, ten (30%) improved in more than one category ofPS, and disease or other prognostic factors.
.5%) improved in more than one score of FN. However, In our study of concurrent WBRT and chemotherapy with
the 33 patients, six (18%) worsened in at least one category cisplatin, vindesine and mitomycin for NSCLC with brain meta-
ind two (6%) worsened in at least one score of FN. At the stasis, the response rate of the brain lesion to treatment was
follow-up of 8.0 months (range 1.4-29.7 months), five 75.8% (including five patients with CRs), and the response rate of
s(15%) had died of local recurrence of brain lesions. Of the the primary lesion to treatment was 18%. Also, the treatment
ients who had neurological dysfunction before the treat- improved at least one grade of performance status in 30% and at
14 had (61%) died of their other metastatic lesions before least one grade ofneurological functions in approximately 55% of
nces of brain lesions, three had died of local recurrence of the patients. Median survival was 8 months and the 1-year survival
sions and six were alive. rate was 40%. Median survival duration and 1-year survival rate,
in our study, were better than the median survival durations (3-6
ial months) and 1-year survival rates (approximately 20%) in the
previously mentioned WBRT-alone trials (Chu and Hilaris, 1961;
median follow-up time of 8.0 months (range 1.4-29.7 Order et al, 1968; West and Maor, 1980), although our study was
,), the median survival time in these 33 patients was 8 uncontrolled and had a bias for patient selection.
and the 1-year survival rate was 40% (Figure 2). Of these The major toxicity in this pilot study was leucopenia. Late toxi-
ents, 26 died because of cancer and seven remained alive city of concurrent WBRT and chemotherapy are becoming more
.3, 13.2, 13.3, 14.5, 14.9 and 29.7 months after the treat- important with the longer survival of patients with metastatic
)fthese 26 patients, 21 had no local brain recurrence. disease (DeAngelis et al, 1989). It may be because of the short
duration of survival in our series that we have experienced no
USSION neurotoxicity. Brain metastasis was the only clinical site of symp-
toms in 15% of the patients in our study. Thus, in spite of concur-
rge studies of the Radiation Therapy Oncology Group (Lee rent radiotherapy and chemotherapy, up to two-thirds of the
)89) demonstrated that more than 75% ofpatients benefited patients died of recurrence oftheir other lesions before recurrence
)matically from WBRT for a short time, but median survival ofbrain lesions.
from 15 to 18 weeks. Brain metastasis as a cause of death We have shown the ability to safely administer concurrent
orted in 31-49% ofpatients. Thus, in spite ofWBRT, up to WBRT and MVP chemotherapy for patients with NSCLC and
the patients eventually developed recurrence of their brain brain metastasis. There is an excellent imaging response rate to
before death due to other metastases. brain tumours, associated with improvement of neurological func-
:nt reports on chemotherapy for patients with brain metas- tion and notable survival rates at a median survival duration and at
om small-cell lung cancer (Kristjansen and Hansen, 1988; 1 year after treatment. To evaluate the true benefit and the best use
al, 1989; Twelves et al, 1990; Postmus et al, 1995), adeno- (accounting for quality of life and toxicity) of this treatment
ima of the lung (Kantarjian et al, 1984), gestational chorio- modality, we are conducting a prospective multicentre randomized
ima (Weed and Hammond, 1980; Sen et al, 1987), germ cell study comparing WBRT with or without concurrent chemotherapy
ancies (Newlands, 1985; Allen et al, 1987) and breast for patients with NSCLC and brain metastasis.
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